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Receptor tyrosine kinase AXL is found upregulated in various types of cancer, including melanoma, 
and correlates with an aggressive cancer phenotype, inducing cell proliferation and epithelial-to-
mesenchymal transition. Additionally, AXL has recently been linked to chemotherapy resistance and 
inhibition of AXL is found to increase DNA damage and reduce expression of DNA repair proteins. In 
light of this, we aimed to investigate if targeting AXL together with DNA damage response proteins 
would be therapeutically beneficial. Using melanoma cell lines, we observed that combined reduction 
of AXL and CHK1/CHK2 signaling decreased proliferation, deregulated cell cycle progression, 
increased apoptosis and reduced expression of DNA damage response proteins. Enhanced therapeutic 
effect of combined- as compared to mono-treatments was further observed in a patient-derived 
xenograft model and, of particular interest, when applying a three-dimensional ex vivo spheroid drug-
sensitivity assay on tumor cells harvested directly from 27 patients with melanoma lymph node 
metastases. 
Together, these results indicate that targeting AXL together with the DNA damage response pathway 
could be a promising treatment strategy in melanoma and that further investigations in patient groups 
lacking treatment alternatives should be pursued.   
 
Keywords: AXL Receptor Protein Tyrosine Kinase, Targeted Molecular Therapy, DNA Damage, 










on February 5, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 23, 2019; DOI: 10.1158/1535-7163.MCT-19-0290 




The incidence of melanoma is increasing worldwide (1). While the prognosis of early stage disease is 
very good, once the cancer progress survival drops dramatically, with over 20 000 melanoma-related 
deaths in Europe annually (2). Approximately 50% of all melanomas harbor activating BRAF 
mutations, with BRAFV600E being the most prevalent. The development of BRAFV600 inhibitors 
vemurafenib and dabrafenib has led to targeted treatment options for patients with these mutations. 
However, almost all patients develop resistance within a year, often due to reactivation of the MAPK 
pathway or other receptor tyrosine kinases independently of BRAF (3,4). Lately, immune checkpoint 
inhibitors, like monoclonal antibodies targeting PD-1 and CTLA-4, have shown promising therapeutic 
effects (5). Yet, only a portion of the patients respond, signifying the importance to identify alternative 
therapeutic strategies.   
The receptor tyrosine kinase AXL; a 138 kDa single-pass transmembrane protein of the TYRO3, 
AXL, MERTK (TAM)-family, has been found overexpressed, both as mRNA and protein, in a wide 
range of cancers (6-8), including melanoma (9). AXL is reported to play a role in cancer progression, 
and has been shown to promote cell proliferation, migration, invasion and epithelial-to-mesenchymal 
transition (EMT) (10-13). Additionally, AXL is shown to mediate resistance to BRAF and MEK 
inhibitors (14,15), as well as immunotherapy (16). All the TAM-family members are activated by the 
vitamin K-dependent ligand Growth arrest-specific protein 6 (GAS6), with AXL having the highest 
affinity for the ligand (17). In addition, AXL can be activated independently of GAS6 through 
aggregation of the protein or by heterodimerization with non-TAM receptor tyrosine kinases (18). 
Activated AXL undergoes homodimerization and autophosphorylation to induce downstream effects 
that activate proteins involved in the PI3K, MAPK14 (p38/MAPK) and MAPK1 (ERK/MAPK) 
pathways (12,13,19).  
Recently AXL expression was found to reduce the sensitivity to chemotherapies, as well as to PARP 
inhibitors (20-22). In ovarian cancer cell lines, an association between AXL and cisplatin resistance 
has been observed (23). Additionally, inhibited AXL expression has been found to induce DNA 
damage and reduce the expression of DNA damage repair proteins (21). Together, these data suggest a 
link between AXL and the DNA damage response (DDR) pathway. Central to the DDR are the 
serine/threonine specific kinases CHK1 and CHK2 that are activated by ATR or ATM, respectively, in 
response to single-stranded (ATR) or double-stranded (ATM) DNA-breaks. CHK1 and CHK2 
transduce signals to effectors such as TP53 (p53), CDC25C, BRCA1 and RAD51, ultimately leading 
to DNA repair, cell cycle arrest and/or apoptosis (24).  
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In this study, we assessed how dual inhibition of AXL and CHK1/CHK2 altered proliferation, signal 
transduction, apoptosis and cell cycle distribution in melanomas. We discovered that targeting or 
inhibiting expression of AXL and CHK1/CHK2 in combination reduced cell proliferation and induced 
cell cycle arrest and apoptosis. We further showed that the combined treatment was superior to mono-
treatment in a patient-derived xenograft (PDX) model and when analyzing drug sensitivity utilizing 
cells harvested directly from melanoma lymph node metastases in a 3D ex-vivo drug-efficacy assay. 
Together, these data suggest that dual targeting of AXL and DDR pathway is a promising treatment 
strategy for melanomas that should be further investigated in patients having developed resistance and 
where few treatment alternatives are available. 
 
Materials and methods: 
Cell lines and patient material 
Melanoma cell lines were established from subcutaneous (Melmet 1) or lymph node (Melmet 5, FEMX-
1 and HHMS) metastatic lesions of patients treated at the Norwegian Radium Hospital, Oslo University 
Hospital (25,26). WM115, WM902B, WM983 and WM1366 cells were a kind gift from Meenhard 
Herlyn, the Wistar cell line collection (Philadelphia, PA, USA). The melanoma cell lines MDA-MB-435 
and MeWo were obtained from American Type Culture Collection (Manassas, VA, USA). All cells 
were routinely checked for mycoplasma by PCR in-house. Melmet 1 and WM1366 cell lines were STR 
fingerprinted (April 2018) by Genetica Cell Line Testing (Burlington, NC, USA). The melanoma cells 
were grown in RPMI-1640 (Sigma Aldrich, St. Louis, MO, USA) supplemented with 5% fetal bovine 
serum (FBS) (Sigma Aldrich, St. Louis, MO, USA) and 2 mM L-glutamine (Lonza, Basel, Switzerland). 
Cells were maintained in a humidified incubator at 37°C and with 5% CO2. All cells were used within 
20 passages of thawing.  
Melanoma lymph node metastases were obtained from patients operated at the Norwegian Radium 
Hospital, Oslo University Hospital. Patient material was collected with written informed consent in 
accordance with the Declaration of Helsinki. The study was approved by the Norway Regional 
Committee for Medical and Health Research Ethics (approval number 2014/2208 and 2015/2434).  
 
Immunoblot, protein analysis and antibodies 
Protein extracts and immunoblots were performed as described (27), with the following exceptions: 
Proteins were lysed in a buffer containing 1% Triton X-100, 50mM Hepes (pH 7.4), 150mM NaCl, 
1.5Mm MgCl2, 1mM EGTA, 100mM NaF, 10mM Na Pyruvate, 1mM Na3VO4 and 10% Glycerol, with 
addition of 10 µL/mL protease and phosphatase inhibitor cocktails (cOmplete Mini and PhosSTOP™, 
Roche, Mannheim, Germany). Antibodies used were: pAXL (#5724), AXL (#8661), pAKT (#9271), 
AKT (#9272), pERK (#9101), pp38 (#9211), p38 (#8690), pSRC (#12432), SRC (#2108),  pp53 
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(#9284), p53 (#2524), CDKN1A (p21) (#2947), pCDC25C (#9528), CDC25C (#4688), pCHK1 
(#2341), CHK1 (#2360), pCHK2 (#2661), CHK2 (#6334), (all diluted 1:1000, Cell Signaling, Boston, 
MA, USA), ERK2 (D2) (#sc-1647, 1:1000, Santa Cruz Biotechnology, Dallas, TX, USA) and α-tubulin 
(DM1A) (#05-829, 1:50 000, Millipore, Burlington, MA, USA). Protein bands were visualized by 
SuperSignal™ West Dura Extended Duration Substrate (Thermo Fisher Scientific, Waltham, MA, 
USA) and exposed in a Syngene G Box. If not otherwise specified, protein lysates were made from cells 
that had been subjected to 400 ng/mL GAS6 (R&D, Minneapolis, MN, USA) and 10 µg/mL Vitamin K 
(Sigma Aldrich, St. Louis, MO) for 60 minutes. USA Simple Western immunoassay was performed 
according to the manufacturer protocol and run on the Peggy Sue™ machine (ProteinSimple, San Jose, 
CA, USA). Antibodies used were AXL (1:100, #8661 Cell Signaling, Boston, MA, USA) and β-actin 
(1:300, #4967 Cell Signaling, Boston, MA, USA). Data was analyzed using the Compass Software 
(Protein Simple, San Jose, CA, USA). 
  
Reagents 
BGB324 (previously known as R428, first described in (28)) was a kind gift from BerGenBio (Bergen, 
Norway). AZD7762 (first described in (29), cat# S1532) and VE-822 (first described in (30,31), 
compound 45, see company website, cat# S7102, for updated structure) was purchased from Selleck 
Chemicals (Huston, TX, USA). Inhibitors, diluted in DMSO, were used at concentrations and time 
periods indicated, with controls receiving the same amount of DMSO as the treatment groups. 
 
RNA interference  
Cells were transfected with 100 nM siRNA using Lipofectamine® 2000 in Opti-MEM Media (Thermo 
Scientific, Waltham, MA, USA) according to manufacturers protocol using the following siRNAs 
targeting AXL: 3 unique 27mer siRNA duplexes (Cat: SR319445, Origene, Rockville, MD, USA) and 
ON-TARGETplus Human AXL siRNA (Cat: J-003104-13-0002, Dharmacon, Lafayette, CO, USA), 
CHK1: ON-TARGETplus Human CHEK1 siRNA (Cat: J-003255-10-0002 and J-003255-11-0002, 
Dharmacon, Lafayette, CO, USA), and CHK2: ON-TARGETplus Human CHEK2 siRNA (Cat: J-
003256-17-0002 and J-003256-18-0002, Dharmacon, Lafayette, CO, USA). ON-TARGETplus Non-
targeting Pool Control siRNA (Cat: D-001810-10-05, Dharmacon, Lafayette, CO, USA) was used as 
control. Cells were left for 48 hours before they were used in further experiments.  
 
In vitro proliferation and Caspase-3/7 cleavage 
For analyzing the effect on proliferation, cells were plated at 15-25% confluency in 96-well or 6-well 
culture plates and left overnight before treatment with drugs for 72 hours. Cell confluence was 
visualized by IncuCyte FLR or IncuCyte Zoom Kinetic Imaging System (Essen Bioscience, Ann Arbor, 
MI, USA) light scanning microscopes. For colony formation assays, 500 or 1000 cells were plated in 6-
well culture plates overnight before drug-containing media was added. After 21 days, colonies were 
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fixated with ice-cold methanol before being stained with 0.05% crystal violet and counted using the 
GelCount™ machine (Oxford Optronix, Abingdon, UK).  
Caspase-3/7 cleavage was determined using the CellPlayer™ 96-well Caspase-3/7 reagent (Essen 
Bioscience Ann Arbor, MI, USA) according to manufacturer’s protocol. In brief, cells were plated to 
yield 10-20% confluency. The following day, drugs and 2.5 µM caspase-3/7 reagent was added. 
Caspase-3/7 cleavage, yielding fluorescent signals, was visualized by IncuCyte FLR or IncuCyte Zoom 
Kinetic Imaging System (Essen Bioscience, Ann Arbor, MI, USA) light scanning microscopes. 
Fluorescence was related to the confluence of the respective well at the respective time points.    
  
Flow cytometry 
Cells were plated at 30% confluency in 6-well plates overnight before incubation with BGB324 and/or 
AZD7762 for 24 hours. Control cells were treated with DMSO. Harvested cells were fixated in 70% ice-
cold methanol and stored at -20ºC for at least 24 hours. Cells were then labeled with 2.4 μL/mL Hoechst 
33258 (Sigma Aldrich, St. Louis, MO, USA) or 500µL propidium iodide Cycloscope™ Reagent 
(Cytognos, Salamanca, Spain) and incubated for 10 minutes shielded from light. H2AX staining was 
performed on fixed cells resuspended and blocked in detergent buffer (0.1% Nonidet P40 (Igepal CA-
630), 6.5mM Na2HPO4, 1.5mM KH2PO4, 2.7mM KCL, 137mM NaCl, 0.5mM EDTA PH 7.5 with 4% 
nonfat milk) before primary incubation with γH2AX antibody (1:500, Abcam, Cambridge, UK) and 
secondary incubation with Alexa Flour® 647 antibody (1:500, Abcam, Cambridge, UK). Cells were 
labeled with 2.4 μL/mL Hoechst 33258 (Sigma Aldrich, St. Louis, MO, USA). Analysis was performed 
using the LSRII flow cytometer (BD Biosciences, San Jose, CA, USA) and analyzed by FlowJo® v10 
software (Ashland, OR, USA). 
 
Invasion and migration assays 
To measure cell invasion, 50 µg matrigel (BD Biosciences, San Jose, CA, USA) was added to Falcon® 
Transparent PET Membrane 24-well 8.0 µm cell culture inserts (Corning, Corning, NY, USA). Newly 
split cells were incubated with 0.1 mCi/mL 3H-Thymidine (Nerliens Mezansky, Oslo, Norway) for 24 
hours. Thereafter, 50 000 serum-starved 3H-Thymidine labeled cells/well were plated in the inserts, in 
RPMI-1640 media (Sigma Aldrich, St. Louis, MO, USA) containing drugs, but without serum. Five 
percent FBS was added to the bottom well in addition to drugs in the same concentration as the top well.  
Cells were harvested by scraping from the bottom and top of the matrigel with a cotton swab that was 
further inserted into tubes containing 4 mL Aquasafe 300 scintillation fluid (Zinsser Analytic, Frankfurt, 
Germany). The invasive ability was determined by comparing 3H-Thymidine-radioactivity as a measure 
of number of cells on the bottom of the matrigel membrane divided by the total radioactivity of cells 
from top and bottom of the membrane.  
Migration was measured by plating 50 000 cells/well in 96-well culture plates and scratching the wells 
the following day by The WoundMaker™ 96-well pin block (Essen Biosciences, Ann Arbord, MI, 
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USA) before adding drug. Cell migration was determined using the Incucyte FLR or Incuzoom Zoom 
Kinetic Imaging System (Essen Biosciences, Ann Arbor, MI, USA), that scan the cells every three 
hours, and with the respective software calculating cell confluence.   
 
 
Ex vivo drug sensitivity assay 
Melanoma lymph node metastases obtained following surgery were disaggregated for one hour by 125 
units collagenase type 2 (Sigma Aldrich, St. Louis, MO, USA) and 2,5 mg/mL DNase (Sigma Aldrich, 
St. Louis, MO, USA). To remove aggregates and debris the cell suspensions were filtered through 100 
μM filters (WVR, Radnor, PA, USA). If necessary, red blood cells were removed using ACK lysing 
buffer (Lonza, Basel, Switzerland). Live cells (15.000-20 000 per well) were seeded in Nunc™ 96-Well 
Polystyrene Round Bottom Microwell plates (Thermo Scientific, Waltham, MA, USA) in RPMI-1640 
(Sigma Aldrich, St. Louis, MO, USA) medium supplemented with 5% FBS, 2 mM L-glutamine, 100 
units/mL penicillin and 0.1 mg/mL streptomycin (all Lonza, Basel, Switzerland) and allowed to form 
three-dimensional spheroids. Drugs were added at indicated concentrations immediately after seeding 
and the cells incubated for 5 days before viability was measured using the CellTiter-Glo® Luminescent 
Cell Viability Assay (Promega, Madison, WI, USA), and analyzed by Fluoroscan Ascent Fl (Thermo 
Scientific, Waltham, MA, USA). The ex-vivo assay was performed once for each patient sample, with at 
least three technical replicates per condition.   
 
In vivo studies 
Eight week old female athymic (foxn1 nu) nude mice were injected subcutaneously with 2x106 Melmet 
1 cells in the right flank. When the tumors reached a volume of approximately 50 mm3 the mice were 
randomized into four groups containing 6-8 mice in each group. 50 mg/kg BGB324 diluted in 0.5% 
Hydroxypropyl Methylcellulose/0.1% Tween-80 was given twice daily by oral gavage and 25 mg/kg 
AZD7762 diluted in 11.3% (2-Hydroxypropyl)-β-cyclodextrin was given intravenously three times a 
week. Treatment duration was fourteen days. Groups not receiving BGB324 and/or AZD7762 were 
administered drug vehicles in the same manner as treatment groups. Treatment toxicity was monitored 
by weight loss measured twice daily on treatment and twice weekly off treatment. Mice with ≥15% 
reduced weight were euthanized. Tumor diameters were measured twice a week by digital calipers and 
tumor volume calculated by the formula 0.5 x length x width2. In line with governmental regulations, 
the mice were euthanized when the tumors reached a diameter of 16 mm and/or a volume of 2000 mm3. 
In vivo data is presented as average tumor volume + standard error of the mean (SEM). All mice were 
bred at the Department of Comparative Medicine, The Norwegian Radium Hospital, housed in rooms 
with alternating light/dark cycles of 12 hours, had ad libitum access to food and water and were kept 
according to regulations of the Norwegian Animal Welfare Act. Animal experiments were approved by 
the Norwegian Animal Research Authority (FOTS approval number 8554). 
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All values represent data average + standard deviation (SD) or SEM. Statistical significance was 
determined by student two-tailed t-test when comparing two groups or one-way ANOVA when 
comparing three groups. Significance over various time points in the animal experiments was 
determined by area under the curve (AUC) analysis. The statistical analyses were performed using 
GraphPad Prism version 7.0 (GraphPad Software, San Diego, CA, USA). P-values of less than 0.05 
were considered significant and marked with asterisks, where p<0.05 = *, p<0.01 = ** and p<0.001 = 
***. Synergism was calculated by the CalcuSyn Software (Biosoft, Cambridge, UK) using the Chou-
Talalay CI method (32). Experiments were performed at least three times with at least three technical 
replicates in each experiment, if not otherwise specified. Immunoblots were performed at least twice 
with independent lysates.  
 
Results: 
Decreased expression or inhibition of AXL reduced proliferation and MAPK and PI3K signaling  
Ten melanoma cell lines were first examined for AXL expression by Simple Western immunoassay 
(Supplementary Figure 1A). Of the three AXL expressing cell lines (Melmet 1, WM1366 and MeWo), 
the two with the highest expression (Melmet 1 and WM1366) were chosen for further studies.  The 
impact of AXL on proliferation was investigated following transfection with two different short 
interfering RNAs (siRNA). As shown in Figure 1A, silencing AXL decreased proliferation and 
reduced colony formation as compared to scrambled siRNA control. The effect on proliferation was 
further confirmed following treatment with the specific small-molecular AXL inhibitor BGB324 (28) 
(Figure 1B). A BGB324 concentration of 2 μM was chosen as a higher dose (3 μM) drastically 
reduced proliferation, suggesting off-target effects at this dose (Supplementary Figure 1B).  Due to the 
role of AXL in epithelial-to-mesenchymal transition (EMT) (33), we next investigated the effect of 
AXL inhibition on migration and invasion. As shown in Supplementary Figure 1C, treatment with 
BGB324 for 24 hours reduced migration and invasion in both cell lines. 
To investigate the effect of targeting AXL on cell signaling, we first confirmed that GAS6 activates 
AXL, as demonstrated by increased Tyrosine 702 phosphorylation (Supplementary Figure 1D). This 
phosphorylation site is found responsible for the general activation of the protein (34). BGB324 
reduced AXL activation in a dose dependent manner in both cell lines (Figure 1C). Of particular note, 
BGB324 increased the total AXL protein level, suggesting an attempt to rescue the reduced AXL 
signaling. Next, the impact of AXL inhibition on downstream signaling pathways was examined. As 
demonstrated in Figure 1C, BGB324 treatment in GAS6 stimulated cells decreased phosphorylation of 
on February 5, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 23, 2019; DOI: 10.1158/1535-7163.MCT-19-0290 
Page 9 of 21 
 
AKT, ERK and particularly SRC, but not p38. These effects were confirmed in siAXL transfected 
cells (Figure 1D).   
 
 
Combined targeting of AXL and the DNA damage response pathway reduced viability and 
tumor growth in melanoma cell lines and patient-derived models. 
The newly discovered link between AXL signaling and DNA damage response (DDR) (21,35) spurred 
us to investigate the effect of combined inhibition of AXL and the DDR. As shown in Figure 2A and 
2B, co-treatment with BGB324 and the CHK1/2 inhibitor AZD7762 synergistically decreased 
proliferation in both Melmet 1 and WM1366 cells. The effect was validated using a three-dimensional 
(spheroid) drug efficacy assay in Melmet 1 cells (Figure 2C). To rule out the possibility of off-target 
effects, we treated the AXL negative cell line WM115 with BGB324 and/or AZD7762 in vitro and 
using the spheroid drug sensitivity assay and only observed reduced proliferation mediated by the 
AZD7762 treatment (Figure 2D), suggesting no off-target effects of the BGB324 treatment. Further, 
reduced proliferation was also observed in siAXL cells treated with AZD7762 compared to treated and 
untreated scrambled control transfected cells (Figure 2E). The transfected cells were more responsive 
to AZD7762 than untransfected cells (Figure 2A), possibly due to the added stress of the transfection.  
To elucidate if the effect was dependent on either CHK1 or CHK2 signaling, we diminished CHK1 or 
CHK2 expression by siRNA before treating the cells with BGB324. Reduced expression of CHK1 or 
CHK2) resulted in slight to no change in proliferation compared to scrambled control transfected cells 
(Figure 3A and 3B). In both cell lines, siCHK1 transfected cells responded with decreased 
proliferation in combination with BGB324 compared to BGB324 treated and untreated control 
transfected cells. This was only significant in cells where CHK1 was completely eradicated (siCHK1 
#1), indicating that even a low expression of CHK1 is enough to partly protect the cells from growth 
inhibition. There was also lower proliferation in siCHK2 transfected cells treated with BGB324 
compared to BGB324 treatment alone, however only significant for one of the siRNA molecules 
(siCHK2 #1). Reducing expression of either CHK1 or CHK2 did not lead to as pronounced decrease 
in proliferation as AZD7762 treatment, neither alone nor in combination with BGB324, suggesting 
that signaling through both proteins must be abolished to maximize the response. To examine this 
hypothesis, we reduced the expression of both CHK1 and CHK2 and observed reduced proliferation in 
the siCHK1 and siCHK2 cells comparable to AZD7762 mono-treatment (Figure 3C and 3D). The 
proliferation of the combined siCHK1 and siCHK2 transfected cells was further reduced when the 
cells were treated with BGB324, yielding results in concordance with cells treated with BGB324 and 
AZD7762.  
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Further, we aimed to determine if reduced proliferation was only dependent on diminished activation 
of the CHK1/2 proteins or if similar effect could be observed when the activation of other DDR 
proteins was lowered. Thus, we inhibited signaling of ATR, mainly working upstream of CHK1, but 
also shown to activate CHK2 (36), using the ATR inhibitor VE-822 ((30,31), compound 45) in 
combination with BGB324 (Figure 3E). In both cell lines, combinatorial treatment with VE-822 and 
BGB324 significantly inhibited cell proliferation compared to each mono-treatment. This illustrates 
that other proteins in the DDR pathway also could be targeted together with AXL and cause reduced 
cell proliferation. Overall, these data demonstrate that inhibiting or reducing the expression of AXL in 
combination with CHK1 and CHK2 or other proteins in the DDR pathway result in decreased cell 
viability.  
The observed effect on proliferation upon simultaneous targeting of AXL and the DDR encouraged us 
to examine if this could also reduce proliferation in patient samples. To this end, cells harvested 
directly from 27 melanoma lymph node metastases were treated with BGB324 and AZD7762 alone or 
in combination and analyzed for effect on viability using the ex vivo drug sensitivity assay.  As shown 
in Figure 4A, the mean effects of the mono-treatments were slightly reduced compared to control, 
however these results were not significant. BGB324 and AZD7762 in combination, however, 
significantly decreased the viability compared to either mono-treatment. Of note, cells from three of 
the patient tumor samples showed increased viability when treated with AZD7762 alone, and in two of 
them, the viability was not reduced following combined treatment.  Finally, the superior effect of the 
combined treatment was confirmed in the mouse Melmet 1 xenograft model (Figure 4B and 4C). 
Whereas the mono-treated mice displayed insignificant reductions in tumor volume, mice treated with 
the combination showed significantly decreased relative tumor volume and prolonged survival time 
compared to untreated controls or following mono-treatments. No significant weight loss was 
observed, indicating that the treatments were well tolerated (Supplementary Figure 2).  
Combined inhibition of AXL and CHK1/CHK2 leads to cell cycle arrest and increased apoptosis  
Due to the observed effects on proliferation and viability we aimed to investigate how reduced AXL 
and CHK1/2 activity alone and in combination affected cell cycle progression and apoptosis. As 
shown in Figure 5A and Supplementary Figure 3A, BGB324 treatment had no effect on cell cycle 
progression in any of the cell lines. AZD7762 treatment, on the other hand, slightly increased the S-
phase fraction in Melmet 1 cells at both 24 and 48 hours post-treatment, but had minimal effect in 
WM1366 cells. Combining the two inhibitors, however, resulted in a considerable S phase arrest in 
Melmet 1 cells at 24 hours, and S phase and G2/M phase arrest at 48 hours. Co-treatment of WM1366 
cells led to G2/M arrest at both 24 hours and 48 hours, whereas S-phase arrest was only observed after 
48 hours. 
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 In addition, in both cell lines a marked sub-G1-peak, suggesting apoptosis or necrosis, was observed 
(Supplementary Figure 3B) following combined treatment with BGB324 and AZD7762. To analyze if 
this reflected apoptosis, cleavage of CASP3 (caspase-3) and CASP7 (caspase-7) was examined using a 
kit yielding a fluorescent signal upon cleavage. As shown in Figure 5B, left panels, mono-treatments 
slightly increased cleavage of caspase-3 and -7, while this was significantly augmented following the 
combined treatment. Caspase-3 cleavage was further confirmed by western blot analysis (Figure 5B, 
right panels), demonstrating caspase-3 cleavage induced by AZD7762 and further increased in cells 
receiving the combined treatment. However, no caspase-3 cleavage was observed in BGB324 treated 
cells as examined by western blot. This is in contrast to the BGB324-induced cleavage of caspase-3 
and -7 observed by the apoptosis assay, suggesting that caspase-7 cleavage plays a more prominent 
role following BGB324 treatment. 
Further, we investigated the molecular effects of BGB324 and/or AZD7762 treatments by western blot 
analyses. As seen in Figure 5C, both compounds alone and in combination reduced the 
phosphorylation of AXL and increased the expression of total AXL. This is in agreement with 
previous reports demonstrating that AZD7762 may reduce AXL phosphorylation (37). Also in line 
with previous reports (38), AZD7762 increased phosphorylation of CHK1 and CHK2 in both cell 
lines, indicating activation of the DDR pathway. In addition, AZD7762 increased Serine 216 
phosphorylation of CDC25C, a downstream effector of CHK1 and CHK2. While BGB324 treatment 
alone did not show any effect on CHK1 and CHK2 phosphorylation compared to control, CDC25C 
was greatly phosphorylated. Phosphorylation and total expression of CHK1, CHK2 and CDC25C was 
reduced in the combined treatment.  
Previous reports have suggested that BGB324 induces activation and expression of H2AFX (H2AX) 
(21). This was not evident in our cell lines (Figure 5C). H2AX phosphorylation and expression was, 
however, observed in AZD7762 treated cells and further increased following combined treatment. The 
H2AX immunoblot results were verified by flow cytometry for WM1366 cells (Supplementary Figure 
3C).  
BGB324 alone had no effect on expression of the DDR proteins p53 or CDKN1A (p21WAF1/Cip1)  in any 
of the two cell lines, whereas AZD7762 and the combination increased p53 protein levels as well as 
Serine 15 phosphorylation in Melmet 1 cells (p53 wild-type). Surprisingly, increased Serine 15 
phosphorylation of p53 was also observed in the p53 mutated cell line WM1366 after treatment with 
AZD7762 alone and in combination with BGB324. In both cell lines, AZD7762 increased the 
expression of p21WAF1/Cip1 and this was further augmented when the two inhibitors were combined. 
While both mono-treatments decreased PI3K and MAPK signaling, enhanced reduction when 
combined was only seen in PI3K signaling in Melmet 1 cells (Supplementary Figure 3D). These data 
were also observed in cells treated with BGB324 and/or VE-822 (Supplementary Figure 3E). 
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Importantly, VE-822 treatment reduced pAXL expression (Supplementary Figure 3E), which was also 
observed in AZD7762 treated cells (Figure 5C). Further, short (10 minutes) exposure to AZD7762 or 
VE-822 monotherapy did not reduce pAXL expression to the extent of BGB324 treatment 
(Supplementary Figure 3F). 
Together, our data indicates that targeting AXL in combination with the DDR pathway reduces 
proliferation, leads to downregulation of DDR response proteins and ultimately results in apoptosis. 
Thus, targeting AXL together with the DDR could be a beneficial treatment option in melanoma.  
 
Discussion 
AXL has been observed overexpressed in various types of cancer and linked to aggressive tumor traits, 
poor prognosis and drug resistance (33,39). In melanoma, acquired resistance to MAPK inhibitors 
(14,40) and immunotherapy (16) has been associated with increased AXL expression, making AXL an 
interesting target to overcome treatment resistance. AXL has also emerged as a promising therapeutic 
strategy in other types of cancers, and currently the AXL inhibitor BGB324 is in phase I/II clinical 
trials alone or in combination with chemotherapy (NCT02488408), erlotinib (NCT02424617), 
pembrolizumab (NCT03184558 and NCT03184571) or dabrafenib and trametinib (NCT02872259).  
In accordance with a previous report (41), AXL was found expressed in 30% of the examined 
melanoma cell lines, and reducing (42,43) or inhibiting (20) AXL expression modestly reduced 
proliferation, migration and invasion. Inhibition of AXL led to decreased AXL-Tyrosine 702 
phosphorylation, indicating less activation of the protein (44). Furthermore, AXL has been found to 
activate the PI3K and MAPK pathways to induce pro-survival and proliferative signals (13). In 
accordance with this, we observed less proliferation and reduced phosphorylation of SRC, AKT and 
ERK upon diminished expression or inhibition of AXL. It has been shown that SRC activity is 
dependent on partnerships with receptor tyrosine kinases such as EGFR and PDGFR (45). These 
receptor tyrosine kinases are closely related to AXL and the substantial decrease in pSCR expression 
at even low levels of BGB324 treatment indicate that SRC activity may be dependent on AXL 
signaling as well. In contrast to what has been observed by others (46), no effect on p38/MAPK 
signaling was observed, potentially due to cell line or cancer type specific differences in p38/MAPK 
mediated stress signaling.  
Recently, inhibition of AXL signaling was found to induce DNA damage (21,35) and it has also been 
proposed that AXL protect cancer cells from fork collapse (35), which is mediated by ATR/ATM-
CHK1/2 signaling. In the current study, we neither observed activation of H2AX nor CHK1/2 
following BGB324 treatment, suggesting that inhibiting AXL does not induce DNA damage in our 
melanoma cell lines. On the other hand, BGB324 led to increased inhibitory phosphorylation (Serine 
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216) of CDC25C, implying cell cycle arrest. CHK1/2 signaling was not activated by BGB324 
treatment, suggesting that CDC25C is inhibited independently of CHK1/2, for instance through 
phosphorylation by MARK3 (c-TAK1), p38/MAPK, CAMK2A, and PRKA (AMPK), as has been 
reported by others (47,48). Additionally, CHK1/2-independent phosphorylation of CDC25C-Serine 
216 must also hold true for AZD7762 treated cells as this inhibitor blocks the downstream signaling of 
CHK1/2 by acting as an ATP competitor (29).  
Because of a prior article describing effects of AXL on DDR (21), we speculated whether treatment 
with BGB324 in combination with a DDR inhibitor could be a beneficial therapeutic strategy in 
melanoma.  In support of this, we found that targeting AXL together with CHK1 and CHK2 inhibited 
proliferation and viability in cell cultures, PDX models and patient material. Decreased proliferation 
was coupled with cell cycle deregulation and increased apoptosis. These data are in accordance with a 
previous finding showing that inhibition of AXL in combination with WEE1, a regulator of cell cycle 
progression downstream of CHK1/2, reduced tumor growth and increased apoptosis in small cell lung 
cancer cells (49). While knockdown of CHK1 or CHK2 resulted in reduced proliferation in 
combination with BGB324, the effect was not as pronounced as when inhibiting or reducing the 
expression of both CHK1 and CHK2. This suggests that redundancy, crosstalk and overlapping roles 
of CHK1 and CHK2 (50) protect the cells from growth inhibition when targeting only one of the 
proteins.  
It has previously been shown that AZD7762 treatment reduces AXL phosphorylation (37), a finding in 
accordance with our results. A direct influence of AZD7762 on AXL phosphorylation might suggest 
that the inhibitory effect on proliferation when combining the two inhibitors solely is caused by 
decreased AXL activity. In a kinase screen of AZD7762, the drug also showed selectivity towards 
AXL, although it was ten times lower for AXL than CHK1/2 (29). To rule out the possibility of 
AZD7762 affecting AXL signaling, we diminished CHK1 or CHK2 expression, or treated cells with 
an ATR inhibitor (VE-822), in combination with BGB324. These experiments led to similar results as 
when using the AZD7762 and BGB324 inhibitors. Importantly, decreased pAXL expression was also 
observed in cells treated with VE-822, suggesting that there is some unknown mechanism of the DDR 
pathway that indirectly or directly targets AXL signaling. This interpretation in strengthened by the 
observation that AZD7762 or VE-822 did not reduce pAXL expression to that of BGB324 treated 
cells in a short (10 minutes) exposure to the drugs. These data demonstrates that the observed 
consequences of the combined treatment is not due to off-target effects of the AZD7762 inhibitor. 
Surprisingly, in the scrambled transfected control cells, we observed lower proliferation when the cells 
were treated with AZD7762 (Figure 2E) compared to the same treatment in untransfected cells (Figure 
2A). This effect was not observed in control transfected cells treated with BGB324 (Figure 3A). We 
do not know the reason for this, but it is shown that lipofectamine treatment increases DNA damage 
and induces cellular stress (51,52). Thus, we speculate that DNA damage and cellular stress produced 
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by the transfection will sensitize the cells for the AZD7762 treatment hindering DDR and inducing 
cellular toxicity. Despite this, cellular proliferation was even further decreased after treatment with 
AZD7762 in combination with AXL knockdown.     
We show here that while AZD7762 treatment resulted in activation and expression of DDR proteins 
such as CHK1, CHK2 and CDC25C, combined treatment with BGB324 diminished the expression of 
these proteins, implying that AXL facilitates the DDR. In line with this, AXL inhibition in 
combination with inhibitors of the DNA repair protein PARP or the cell cycle regulator WEE1 has 
shown to reduce the expression of DDR and DNA repair proteins (21,49). Further, previous reports 
have shown that accumulation of p53 and p21WAF1/Cip1 following DNA damage is associated with 
reduced expression of CHK1 (53), CHK2 (54) and CDC25C (55), which was also observed in this 
study. We do not know, however, if the accumulation of p53 and p21WAF1/Cip1 precedes the 
downregulation of DDR protein expression, or if the downregulation of these proteins promotes 
increased p53 and p21 WAF1/Cip1 activation and/or expression. p53 and p21WAF1/Cip1 activation and/or 
expression play a role in triggering apoptosis, and in line with this, we observed that the combined 
inhibition of AXL and CHK1/2 led to apoptosis through  cleavage of caspase-3 and-7. AZD7762 
treatment caused a more pronounced increase in caspase-3 cleavage, as assessed by immunoblot, than 
BGB324 treatment, while the caspase-3 and -7 cleavage was approximately similar in the two mono-
treatments as measured by the fluorescent reagent. This indicates that BGB324 activates caspase-7 to a 
larger degree than AZD7762 treatment. 
The observed effects on cell viability upon combined AXL and CHK1/2 targeting in cell lines, was 
further verified using  disaggregated cells from melanoma lymph node metastases in an ex vivo drug 
efficacy assay. The added effect of the combined treatment relative to the mono-treatments was less 
pronounced in the ex vivo assay, probably due to the presence of non-malignant cells in the lymph 
node metastases or by cells that do not express AXL. Despite this, the assay clearly distinguishes 
patient-derived tumor cells with different sensitivity to the applied drugs. Previously, we have 
confirmed platinum chemotherapy resistance in ovarian cancer patients (56), and recently we 
demonstrated concordance between response to the mutated BRAF inhibitor vemurafenib and 
BRAF/NRAS mutation status when analyzing tumor cells from melanoma lymph node metastases in 
the ex vivo assay (57). Together, these data show that the ex vivo assay is able to reflect patient 
response to various drugs, and should be further evaluated as a supplement to guide treatment in 
patients having developed resistance against standard treatment regimes. 
To conclude, AXL is shown to be upregulated in melanoma and its expression is associated with 
treatment resistance, making AXL an interesting target to overcome resistance to therapy. In this 
study, we investigated the effect of targeting AXL together with the DDR and found that this 
combination resulted in reduced cell proliferation and tumor growth. We show that dual inhibition of 
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AXL and the DDR result in cell cycle retention and increased apoptosis through downregulation of 
CHK1, CHK2 and CDC25C, suggesting that AXL facilitate the DDR. These data strongly suggest that 
targeting AXL together with the DDR may be a promising treatment strategy for melanoma and 
studies to further investigate this possibility is highly warranted.   
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Figure 1: Effects of diminished AXL expression or activity on cell proliferation and signaling.  
A) Proliferation of Melmet 1 and WM1366 cells with siRNA-mediated silencing of AXL expression 
measured by IncuCyte Live imaging 72 hours after plating (n=3) (left panels) or by colony formation 
21 days after plating (right panels). Colony formation shows an average of two independent 
experiments for Melmet 1 cells and three independent experiments for WM1366 cells. B) Melmet 1 
and WM1366 cells treated with 2µM BGB324 (AXL inhibitor) reduced proliferation as measured by 
the IncuCyte Live imaging system (n=3). Representative immunoblot analysis of indicated proteins 
following C) treatment with indicated concentrations of BGB324 for 24 hours and D) siRNA-
mediated AXL silencing. Control cells were treated with C) DMSO or D) scrambled siRNA. 
Immunoblots were performed at least twice with independent lysates. p<0.05 = *, p<0.01 = ** and 
p<0.001 = ***.  
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Figure 2: Inhibition of AXL and CHK1 and CHK2 signaling reduced proliferation in melanoma 
cell lines. 
A) Dual treatment with 2 μM BGB324 and 1 μM AZD7762 reduced average proliferation in Melmet 1 
and WM1366 melanoma cell lines. B) Combination index (CI) values as estimated by the Chou-
Talalay method using average proliferation of indicated doses of BGB324 and AZD7762. CI < 1 
indicates synergy. C) Proliferation of Melmet 1 cells treated with 2 µM BGB324 and/or 1 µM 
AZD7762 measured by the 3D spheroid assay correlates to what is observed in vitro. D) Proliferation 
measured by Incucyte Live imaging system (left panel) and using the 3D spheroid assay (right panel) 
in the AXL-negative cell line WM115 treated with BGB324 and/or AZD7762.  E)  Silenced AXL 
expression in combination with 1 μM AZD7762 reduced proliferation. Δ equals p value = 0.07. 
Proliferation was measured 72 hours after drug addition by the Incucyte Live imaging system (in 
vitro) or after 5 days using CellTiter-Glo® Luminescent assay (3D spheroid assay). Control cells were 
treated with DMSO. Experiments show an average of three biological replicates + SEM. p<0.05 = 
*and p<0.01 = **.  
Figure 3: Treatment with BGB324 and siCHK1 and/or siCHK2 or the ATR inhibitor VE-822 
reduced cell proliferation. 
A) siRNA-mediated silencing of CHK1 (left panels) or CHK2 (right panels) before treatment with 
BGB324 reduced proliferation in melanoma cell lines. B) Immunoblot of CHK1 or CHK2 protein 
expression in cells transfected with siRNAs targeting either CHK1 (right panels) or CHK2 (left 
panels). C) Diminished expression of both CHK1 and CHK2 further reduced proliferation in 
combination with BGB324 treatment. D) Immunoblot of CHK1 and CHK2 expression in cells 
transfected with siCHK1 and siCHK2. E) Proliferation after drug addition of BGB324 and indicated 
doses of the ATR inhibitor VE-822. All proliferation data was measured by Incucyte Live imaging and 
the data shows average values relative to control cells calculated 72 hours after drug addition of at 
least three independent experiments + SEM. BGB324: 2 μM. Control cells were treated with DMSO. 
p<0.05 = *, p<0.01 = ** and p<0.001 = ***. Δ equals p value = 0.0512. 
Figure 4: Dual inhibition of AXL and CHK1/2 reduced cell viability in patient tumor samples 
and inhibited tumor growth in vivo. 
A) Lymph node metastases from melanoma patients were disaggregated, cells were plated as spheres 
and treated with 2 µM BGB324 and/or 2µM AZD7762 for five days. Cell viability was measured by 
CellTiter-Glo® and related to control samples treated with DMSO (n=27 patients). B) Tumor volume 
relative to the volume at day of treatment initiation of Melmet 1 xenografts treated with 50 mg/kg 
BGB324 twice daily and/or 25 mg/kg AZD7762 three times a week for two weeks. Controls were 
treated with drug vehicle(s). There were 6-8 mice per group. C) Kaplan-Meier survival curve showing 
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percentage mice in B) still alive as function of time. The experiment was terminated at day 62 and all 
mice still alive (n=9) were censored. p<0.05 = *and p<0.01 = **. 
Figure 5: Combined treatment of BGB324 and AZD7762 leads to cell cycle arrest and apoptosis 
with reduced expression of cell cycle regulators. 
A) Cell cycle distribution of Melmet 1 and WM1366 treated with BGB324 and/or AZD7762 for 24 or 
48 hours measured by Hoechst 33258 incorporation and analyzed by Flow Cytometry. The data is 
shown as average of three independent experiments for 24 hours and two independent experiments for 
48 hours + SEM.  B) Average apoptosis measured by fluorescence staining of a caspase-3/-7 reagent 
by IncuCyte Live imaging. Fluorescent intensity was related to number of cells in each well and to 
control 72 hours after treatment with BGB324 and/or AZD7762 (left panels). Apoptosis experiments 
show an average of three biological experiments + SEM. Protein expression in total lysates of Melmet 
1 and WM1366 cells treated with BGB324 and/or AZD7762 as shown by a representative immunoblot 
for proteins indicated (right panels).  C) Protein expression in total lysates of Melmet 1 and WM1366 
cells treated with BGB324 and/or AZD7762  for 24 hours as shown by a representative immunoblot 
for proteins indicated. Immunoblots were performed at least twice with independent lysates.  In all 
experiments, control cells were treated with DMSO. Concentration of BGB324: 2 μM and AZD7762: 
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